| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
310,240,000 |
| Market
Cap: |
6.79(B) |
| Last
Volume: |
2,475,481 |
Avg
Vol: |
2,443,625 |
| 52
Week Range: |
$18.78 - $24.13 |
|
| Level
I Sector: |
Industrials |
| Level
II Sector: |
Diversified Services |
| Level
III Sector: |
Research Services |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Exelixis is an oncology-focused biotechnology company that engages in the discovery, development and commercialization of new medicines for cancers. Co.'s products include: CABOMETYX® (cabozantinib) tablets approved for renal cell carcinoma, and for previously treated hepatocellular carcinoma; and COMETRIQ® (cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer. The other products are: COTELLIC® (cobimetinib), an inhibitor of MEK approved as part of a combination regimen to treat forms of melanoma; and MINNEBRO® (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved for the treatment of hypertension in Japan.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
190,000 |
310,409 |
310,409 |
310,409 |
| Total Buy Value |
$3,932,734 |
$6,534,772 |
$6,534,772 |
$6,534,772 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
1 |
2 |
2 |
2 |
| Total Shares Sold |
66,225 |
325,783 |
532,046 |
1,028,448 |
| Total Sell Value |
$1,469,691 |
$7,234,582 |
$11,431,100 |
$20,278,991 |
| Total People Sold |
2 |
4 |
5 |
11 |
| Total Sell Transactions |
2 |
8 |
12 |
26 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Lamb Peter |
EVP, Scientific Strategy & CSO |
• – – |
2021-08-16 |
4 |
OE |
$1.90 |
$104,500 |
D/D |
55,000 |
444,467 |
|
- |
|
| Schwab Gisela Md |
Pres, Prod Dev & Med Aff & CMO |
• – – |
2021-07-26 |
4 |
OE |
$4.20 |
$168,000 |
D/D |
40,000 |
689,078 |
|
- |
|
| Schwab Gisela Md |
Pres, Prod Dev & Med Aff & CMO |
• – – |
2021-07-21 |
4 |
OE |
$4.20 |
$147,000 |
D/D |
35,000 |
649,078 |
|
- |
|
| Lamb Peter |
EVP, Scientific Strategy & CSO |
• – – |
2021-07-15 |
4 |
AS |
$17.47 |
$1,048,200 |
D/D |
(60,000) |
389,467 |
|
4% |
|
| Lamb Peter |
EVP, Scientific Strategy & CSO |
• – – |
2021-07-15 |
4 |
OE |
$1.90 |
$114,000 |
D/D |
60,000 |
449,467 |
|
- |
|
| Cohen Charles |
Director |
– • – |
2021-07-06 |
4 |
OE |
$3.13 |
$377,200 |
D/D |
80,000 |
261,375 |
|
- |
|
| Lamb Peter |
EVP, Scientific Strategy & CSO |
• – – |
2021-06-17 |
4 |
AS |
$22.18 |
$1,330,800 |
D/D |
(60,000) |
389,467 |
|
-2% |
|
| Lamb Peter |
EVP, Scientific Strategy & CSO |
• – – |
2021-06-17 |
4 |
OE |
$1.90 |
$114,000 |
D/D |
60,000 |
449,467 |
|
- |
|
| Wyszomierski Jack L |
Director |
– • – |
2021-05-27 |
4 |
A |
$0.00 |
$0 |
D/D |
8,299 |
239,888 |
|
- |
|
| Freire Maria C |
Director |
– • – |
2021-05-27 |
4 |
A |
$0.00 |
$0 |
D/D |
8,299 |
40,126 |
|
- |
|
| Papadopoulos Stelios |
Director |
– • – |
2021-05-27 |
4 |
A |
$0.00 |
$0 |
D/D |
16,424 |
1,304,551 |
|
- |
|
| Smith Julie |
Director |
– • – |
2021-05-27 |
4 |
A |
$0.00 |
$0 |
D/D |
16,424 |
32,725 |
|
- |
|
| Poste George |
Director |
– • – |
2021-05-27 |
4 |
A |
$0.00 |
$0 |
D/D |
16,424 |
173,614 |
|
- |
|
| Marchesi Vincent T |
Director |
– • – |
2021-05-27 |
4 |
A |
$0.00 |
$0 |
D/D |
8,299 |
74,414 |
|
- |
|
| Haley Patrick J. |
EVP, Commercial |
• – – |
2021-05-18 |
4 |
S |
$24.73 |
$360,885 |
D/D |
(14,593) |
280,994 |
|
15% |
|
| Hessekiel Jeffrey |
EVP, General Counsel & Sec |
• – – |
2021-05-17 |
4 |
AS |
$25.39 |
$457,020 |
D/D |
(18,000) |
604,822 |
|
-19% |
|
| Haley Patrick J. |
EVP, Commercial |
• – – |
2021-05-15 |
4 |
D |
$25.56 |
$77,345 |
D/D |
(3,026) |
295,587 |
|
- |
|
| Marchesi Vincent T |
Director |
– • – |
2021-05-14 |
4 |
S |
$25.04 |
$1,001,600 |
D/D |
(40,000) |
66,115 |
|
20% |
|
| Marchesi Vincent T |
Director |
– • – |
2021-05-14 |
4 |
OE |
$6.30 |
$252,000 |
D/D |
40,000 |
106,115 |
|
- |
|
| Poste George |
Director |
– • – |
2021-05-14 |
4 |
S |
$24.97 |
$1,018,826 |
D/D |
(40,802) |
157,190 |
|
20% |
|
| Morrissey Michael M |
President and CEO |
• • – |
2021-05-14 |
4 |
GA |
$0.00 |
$0 |
I/I |
19,722 |
1,038,789 |
|
- |
|
| Morrissey Michael M |
President and CEO |
• • – |
2021-05-14 |
4 |
GD |
$0.00 |
$0 |
D/D |
19,722 |
491,813 |
|
- |
|
| Schwab Gisela Md |
Pres, Prod Dev & Med Aff & CMO |
• – – |
2021-05-13 |
4 |
AS |
$25.38 |
$2,538,000 |
D/D |
(100,000) |
614,078 |
|
-21% |
|
| Schwab Gisela Md |
Pres, Prod Dev & Med Aff & CMO |
• – – |
2021-05-13 |
4 |
OE |
$1.90 |
$190,000 |
D/D |
100,000 |
714,078 |
|
- |
|
| Morrissey Michael M |
President and CEO |
• • – |
2021-05-12 |
4 |
D |
$25.16 |
$761,794 |
D/D |
(30,278) |
511,535 |
|
- |
|
985 Records found
|
|
Page 10 of 40 |
|
|
